CH Biotech R&D Co., Ltd.
CH Biotech R&D Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of agriculture chemicals in Taiwan, the United States, and internationally. It offers fertilizers and plant growth regulators; and provides biotechnology services. The company was incorporated in 2013 and is headquartered in Nantou City, Taiwan.
CH Biotech R&D Co., Ltd. (6534) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.042x
Based on the latest financial reports, CH Biotech R&D Co., Ltd. (6534) has a cash flow conversion efficiency ratio of -0.042x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-109.75 Million) by net assets (NT$2.62 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
CH Biotech R&D Co., Ltd. - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how CH Biotech R&D Co., Ltd.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
CH Biotech R&D Co., Ltd. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of CH Biotech R&D Co., Ltd. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Circus SE
XETRA:CA1
|
N/A |
|
Gamehost Inc
PINK:GHIFF
|
0.058x |
|
TiumBio Co. Ltd
KQ:321550
|
-0.130x |
|
Barton Gold Holdings Ltd
AU:BGD
|
-0.172x |
|
Gentas Genel Metal Sanayi ve Ticaret AS
IS:GENTS
|
0.066x |
|
Pharmosa Biopharm Inc.
TWO:6875
|
-0.034x |
|
Asia Plus Group Holdings PCL
BK:ASP
|
0.253x |
|
DEFAMA Deutsche Fachmarkt AG
XETRA:DEF
|
0.065x |
Annual Cash Flow Conversion Efficiency for CH Biotech R&D Co., Ltd. (2020–2024)
The table below shows the annual cash flow conversion efficiency of CH Biotech R&D Co., Ltd. from 2020 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$2.65 Billion | NT$538.44 Million | 0.203x | -22.22% |
| 2023-12-31 | NT$2.52 Billion | NT$659.15 Million | 0.262x | -21.88% |
| 2022-12-31 | NT$2.09 Billion | NT$698.97 Million | 0.335x | +118.24% |
| 2021-12-31 | NT$1.72 Billion | NT$264.36 Million | 0.153x | -2.52% |
| 2020-12-31 | NT$1.48 Billion | NT$232.91 Million | 0.157x | -- |